Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy

• Verfasst von: Litviakov, Nikolai V. [VerfasserIn]
• Verfasst von: Kzhyshkowska, Julia [VerfasserIn]
• Titel: Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy
• Verf.angabe: Nikolai Litviakov, Matvey Tsyganov, Irina Larionova, Marina Ibragimova, Irina Deryusheva, Polina Kazantseva, Elena Slonimskaya, Irina Frolova, Eugeniy Choinzonov, Nadezhda Cherdyntseva, Julia Kzhyshkowska
• E-Jahr: 2018
• Jahr: 4 May 2018
• Umfang: 11 S.
• Fussnoten: Gesehen am 22.10.2020
• Titel Quelle: Enthalten in: Cancer chemotherapy and pharmacology
• Ort Quelle: Berlin : Springer, 1978
• Jahr Quelle: 2018
• Band/Heft Quelle: 82(2018), 1, Seite 99-109
• ISSN Quelle: 1432-0843
• DOI: doi:10.1007/s00280-018-3594-8
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1736245171

Abstract

High activity of enzyme TOP2a in tumor cells is known to be associated with sensitivity to anthracycline chemotherapy, but 20% of such patients do not show clinical response. Tumor microenvironment, including tumor-associated macrophages (TAM), is an essential factor defining the efficiency of chemotherapy. In the present study, we analyzed the expression of M2 macrophage markers, YKL-39 and CCL18, in tumors of breast cancer patients received anthracycline-based NAC.